IBRN - ETF AI Analysis
Top Page
iShares Neuroscience and Healthcare ETF (IBRN)
IBRN, the iShares Neuroscience and Healthcare ETF, has a solid but mixed overall rating, reflecting a blend of strong, established biotech names and higher-risk early-stage companies. High-quality holdings like Neurocrine (NBIX), Alkermes (ALKS), Argenx (ARGX), Biogen (BIIB), and ACADIA (ACAD) support the fund’s quality through strong financial performance, positive earnings sentiment, and promising pipelines. However, more speculative holdings such as Edgewise Therapeutics (EWTX), Scholar Rock (SRRK), Praxis (PRAX), and Dianthus (DNTH) introduce meaningful risk, and the fund’s focus on neuroscience and biotech means investors are exposed to sector-specific volatility and clinical trial uncertainty.
IBRN vs. SPDR S&P 500 ETF (SPY)
- AUM
- 6.35M
- Region
- Global
- Expense Ratio
- 0.47%
- Beta
- 1.11
- Issuer
- iShares
- Inception Date
- Aug 24, 2022
- Dividend Yield
- 1.02%
- Asset Class
- Equity
- Index Tracked
- NYSE FactSet Global Neuro Biopharma and MedTech Index
IBRN Summary
The iShares Neuroscience and Healthcare ETF (IBRN) tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index, focusing on health care companies working on brain-related drugs, treatments, and medical technology. It mainly holds U.S. biotech and pharma firms, including well-known names like Biogen and Neurocrine, along with other specialized drug developers. Someone might invest in IBRN if they want growth potential from cutting-edge medical research and to bet on rising demand for new neurological therapies. However, this fund is heavily concentrated in health care and biotech, so its price can swing a lot and may rise or fall sharply with news about drug trials and approvals.
How much will it cost me?
This ETF has an expense ratio of 0.47%, which means you’ll pay about $4.70 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because this fund is more specialized and focused on a niche area of healthcare, which typically costs more to manage.
What would affect this ETF?
This ETF could benefit if global healthcare spending grows, new neurological drugs and treatments from companies like Biogen and Neurocrine succeed, and supportive regulations encourage innovation across the pharma and biotech sectors worldwide. On the downside, it may be hurt by stricter drug approval rules, setbacks in clinical trials, changes in healthcare policy or pricing, and market volatility that often affects specialized, research-focused healthcare companies.
IBRN Top 10 Holdings
IBRN is a pure play on global neuroscience and biotech, with performance largely steered by a handful of specialized drug developers. Biogen and Argenx are among the steadier, rising anchors, benefiting from solid pipelines and revenue growth. On the more volatile side, Alkermes and Dianthus are powering ahead but with a bumpier ride, while Edgewise Therapeutics and Scholar Rock are more like high‑octane engines that occasionally misfire, reflecting early‑stage risk. Overall, the fund is tightly concentrated in health care innovators, with limited diversification beyond this niche.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 BIIB | Biogen | 5.58% | $354.36K | $37.04B | 67.04% | 74Outperform |
 ALKS | Alkermes | 4.65% | $295.39K | $7.32B | 45.24% | 80Outperform |
 EWTX | Edgewise Therapeutics | 4.50% | $285.85K | $4.27B | 160.33% | 40Underperform |
 NBIX | Neurocrine | 4.47% | $283.86K | $14.51B | -0.68% | 80Outperform |
 PTCT | PTC Therapeutics | 4.41% | $280.28K | $5.06B | -9.30% | 72Outperform |
 ARGX | Argenx Se | 4.12% | $261.85K | $55.10B | 7.58% | 79Outperform |
 PRAX | Praxis Precision Medicines | 3.57% | $226.56K | $7.06B | 42.10% | 58Neutral |
 SRRK | Scholar Rock Holding | 3.68% | $233.51K | $5.05B | 44.77% | 50Neutral |
 ACAD | ACADIA Pharmaceuticals | 3.52% | $223.31K | $3.40B | -9.20% | 75Outperform |
 DNTH | Dianthus Therapeutics | 3.52% | $223.65K | $4.29B | 130.78% | 61Neutral |
IBRN Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBRN, the sentiment is Negative. The current price of 31.36 is below the 20-day moving average (MA) of 31.72, below the 50-day MA of 35.45, and below the 200-day MA of 34.79, indicating a bearish trend. The MACD of -1.13 indicates Negative momentum. The RSI at 39.81 is Neutral, neither overbought nor oversold. The STOCH value of 80.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBRN.
IBRN Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IBRN | $31.36 | $30.00(-4.35% Downside) | $6.35M | 0.47% | 52Neutral |
 OZEM | $29.64 | $47.83(61.37% Upside) | $56.12M | 0.59% | 55Neutral |
 HRTS | $37.46 | $45.01(20.16% Upside) | $55.53M | 0.75% | 67Neutral |
 FMED | $31.54 | $43.99(39.49% Upside) | $52.07M | 0.50% | 59Neutral |
 PSIL | $20.64 | $54.49(164.01% Upside) | $45.18M | 1.00% | 45Neutral |
 MEDI | $33.54 | $44.49(32.64% Upside) | $43.16M | 0.80% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IBRN | iShares Neuroscience and Healthcare ETF | 31.36 | 1.48 | 4.95% | |
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 29.64 | 2.02 | 7.33% | |
| HRTS | Tema Cardiovascular and Metabolic ETF | 37.46 | 5.21 | 16.16% | |
| FMED | Fidelity Disruptive Medicine ETF | 31.54 | 4.78 | 17.85% | |
| PSIL | AdvisorShares Psychedelics ETF | 20.64 | 2.29 | 12.48% | |
| MEDI | Harbor Health Care ETF | 33.54 | 3.35 | 11.11% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.